South Korea
· Delayed Price · Currency is KRW Korean Drug Statistics
Total Valuation
Korean Drug has a market cap or net worth of KRW 53.69 billion. The enterprise value is 28.00 billion.
| Market Cap | 53.69B |
| Enterprise Value | 28.00B |
Important Dates
The next estimated earnings date is Wednesday, August 27, 2025.
| Earnings Date | Aug 27, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Korean Drug has 10.91 million shares outstanding. The number of shares has decreased by -0.28% in one year.
| Current Share Class | 10.91M |
| Shares Outstanding | 10.91M |
| Shares Change (YoY) | -0.28% |
| Shares Change (QoQ) | -1.69% |
| Owned by Insiders (%) | 50.60% |
| Owned by Institutions (%) | n/a |
| Float | 5.39M |
Valuation Ratios
The trailing PE ratio is 118.26.
| PE Ratio | 118.26 |
| Forward PE | n/a |
| PS Ratio | 0.80 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | 5.29 |
| P/OCF Ratio | 4.86 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.82, with an EV/FCF ratio of 2.76.
| EV / Earnings | 62.60 |
| EV / Sales | 0.42 |
| EV / EBITDA | 8.82 |
| EV / EBIT | 24.72 |
| EV / FCF | 2.76 |
Financial Position
The company has a current ratio of 6.43, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.43 |
| Quick Ratio | 4.30 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.01 |
| Interest Coverage | 254.09 |
Financial Efficiency
Return on equity (ROE) is 0.57% and return on invested capital (ROIC) is 0.91%.
| Return on Equity (ROE) | 0.57% |
| Return on Assets (ROA) | 0.75% |
| Return on Invested Capital (ROIC) | 0.91% |
| Return on Capital Employed (ROCE) | 1.41% |
| Revenue Per Employee | 247.31M |
| Profits Per Employee | 1.66M |
| Employee Count | 270 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 1.73 |
Taxes
In the past 12 months, Korean Drug has paid 1.52 billion in taxes.
| Income Tax | 1.52B |
| Effective Tax Rate | 77.26% |
Stock Price Statistics
The stock price has decreased by -20.13% in the last 52 weeks. The beta is 0.43, so Korean Drug's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -20.13% |
| 50-Day Moving Average | 4,822.20 |
| 200-Day Moving Average | 4,859.28 |
| Relative Strength Index (RSI) | 58.58 |
| Average Volume (20 Days) | 14,608 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Korean Drug had revenue of KRW 66.77 billion and earned 447.34 million in profits. Earnings per share was 41.60.
| Revenue | 66.77B |
| Gross Profit | 31.42B |
| Operating Income | 1.13B |
| Pretax Income | 1.97B |
| Net Income | 447.34M |
| EBITDA | 3.18B |
| EBIT | 1.13B |
| Earnings Per Share (EPS) | 41.60 |
Balance Sheet
The company has 25.75 billion in cash and 68.23 million in debt, giving a net cash position of 25.68 billion or 2,353.79 per share.
| Cash & Cash Equivalents | 25.75B |
| Total Debt | 68.23M |
| Net Cash | 25.68B |
| Net Cash Per Share | 2,353.79 |
| Equity (Book Value) | 77.16B |
| Book Value Per Share | 7,133.53 |
| Working Capital | 55.76B |
Cash Flow
In the last 12 months, operating cash flow was 11.04 billion and capital expenditures -884.14 million, giving a free cash flow of 10.15 billion.
| Operating Cash Flow | 11.04B |
| Capital Expenditures | -884.14M |
| Free Cash Flow | 10.15B |
| FCF Per Share | 930.44 |
Margins
Gross margin is 47.05%, with operating and profit margins of 1.70% and 0.67%.
| Gross Margin | 47.05% |
| Operating Margin | 1.70% |
| Pretax Margin | 2.95% |
| Profit Margin | 0.67% |
| EBITDA Margin | 4.76% |
| EBIT Margin | 1.70% |
| FCF Margin | 15.20% |
Dividends & Yields
This stock pays an annual dividend of 160.00, which amounts to a dividend yield of 3.23%.
| Dividend Per Share | 160.00 |
| Dividend Yield | 3.23% |
| Dividend Growth (YoY) | 6.67% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 386.80% |
| Buyback Yield | 0.28% |
| Shareholder Yield | 3.51% |
| Earnings Yield | 0.83% |
| FCF Yield | 18.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korean Drug has an Altman Z-Score of 5.1 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.1 |
| Piotroski F-Score | 6 |